BIOMARKER:

BCR-ABL1 V299L

Entrez ID:

Related biomarkers:

‹

›

BCR-ABL1 V299L BCR-ABL1 V299L	Acute Lymphocytic Leukemia ALL	BCR-ABL1 V299L BCR-ABL1 V299L	Acute Lymphocytic Leukemia ALL	dasatinib Resistant: A2 - Guideline	dasatinib Resistant: A2 - Guideline
BCR-ABL1 V299L BCR-ABL1 V299L	Chronic Myeloid Leukemia CML	BCR-ABL1 V299L BCR-ABL1 V299L	Chronic Myeloid Leukemia CML	bosutinib Resistant: A2 - Guideline	bosutinib Resistant: A2 - Guideline
BCR-ABL1 V299L BCR-ABL1 V299L	Chronic Myeloid Leukemia CML	BCR-ABL1 V299L BCR-ABL1 V299L	Chronic Myeloid Leukemia CML	dasatinib Resistant: A2 - Guideline	dasatinib Resistant: A2 - Guideline
BCR-ABL1 V299L BCR-ABL1 V299L	Acute Lymphocytic Leukemia ALL	BCR-ABL1 V299L BCR-ABL1 V299L	Acute Lymphocytic Leukemia ALL	bosutinib Resistant: A2 - Guideline	bosutinib Resistant: A2 - Guideline
BCR-ABL1 V299L BCR-ABL1 V299L	Chronic Myeloid Leukemia CML	BCR-ABL1 V299L BCR-ABL1 V299L	Chronic Myeloid Leukemia CML	nilotinib Sensitive: D – Preclinical	nilotinib Sensitive: D – Preclinical
BCR-ABL1 V299L BCR-ABL1 V299L	Acute Lymphocytic Leukemia ALL	BCR-ABL1 V299L BCR-ABL1 V299L	Acute Lymphocytic Leukemia ALL	crizotinib Sensitive: D – Preclinical	crizotinib Sensitive: D – Preclinical
BCR-ABL1 V299L BCR-ABL1 V299L	Acute Lymphocytic Leukemia ALL	BCR-ABL1 V299L BCR-ABL1 V299L	Acute Lymphocytic Leukemia ALL	GSK1363089 Sensitive: D – Preclinical	GSK1363089 Sensitive: D – Preclinical
BCR-ABL1 V299L BCR-ABL1 V299L	Acute Lymphocytic Leukemia ALL	BCR-ABL1 V299L BCR-ABL1 V299L	Acute Lymphocytic Leukemia ALL	cabozantinib capsule Sensitive: D – Preclinical	cabozantinib capsule Sensitive: D – Preclinical
BCR-ABL1 V299L BCR-ABL1 V299L	Acute Lymphocytic Leukemia ALL	BCR-ABL1 V299L BCR-ABL1 V299L	Acute Lymphocytic Leukemia ALL	vandetanib Sensitive: D – Preclinical	vandetanib Sensitive: D – Preclinical
BCR-ABL1 V299L BCR-ABL1 V299L	Chronic Myeloid Leukemia CML	BCR-ABL1 V299L BCR-ABL1 V299L	Chronic Myeloid Leukemia CML	imatinib Sensitive: D – Preclinical	imatinib Sensitive: D – Preclinical